BioCentury | Oct 30, 2014
Strategy

Bayer's Bay Area formula

...prevent blood clotting-one of Bayer's key therapeutic areas-while ProLynx's technology extends the half-life of drugs. Daniel Santi...
BioCentury | Apr 23, 2012
Emerging Company Profile

ProLynx: Hitting the links

...reduce a drug's biological activity and preclude intracellular action, according to ProLynx co-founder and President Daniel Santi...
...Disease focus: Drug delivery, endocrine/metabolic, cancer Clinical status: Preclinical Founded: 2009 by Gary Ashley and Daniel Santi...
BioCentury | Jun 30, 2008
Strategy

Pfizer fleshing out its model

...“What is novel about this deal is the unspecified nature of the research projects,” said Daniel Santi...
BioCentury | Jun 2, 2008
Strategy

Kosan Chronicles

...data miss the primary endpoint of change in levels of prostate-specific antigen (PSA).I. 2/14/06 - Daniel Santi...
BioCentury | Feb 20, 2006
Company News

Kosan management update

...Kosan Biosciences Inc. (KOSN), Hayward, Calif. Business: Cancer, Infectious Resigned: Daniel Santi as chairman and CEO; Robert...
BioCentury | Feb 16, 2006
Company News

Santi leaving Kosan

...Cancer and infectious disease company Kosan (KOSN) said co-founder Daniel Santi resigned as chairman and CEO. He...
BioCentury | Aug 22, 2005
Finance

Ebb & Flow

...proposed the financing on Aug. 5, the stock was at $9.65. KOSN Chairman and CEO Daniel Santi...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech Capital, increasing Alta's ownership in the polyketide developer to 9.9%. Company Chairman and CEO Daniel Santi...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech Capital, increasing Alta's ownership in the polyketide developer to 9.9%. Company Chairman and CEO Daniel Santi...
BioCentury | Dec 18, 2000
Emerging Company Profile

Prospect Genomics Inc.

...Andrej Sali, Ken Dill, Peter Kollman, Irwin Kuntz, Richard Goold, Tod Klingler, William Rutter, and Daniel Santi...
Items per page:
1 - 10 of 13
BioCentury | Oct 30, 2014
Strategy

Bayer's Bay Area formula

...prevent blood clotting-one of Bayer's key therapeutic areas-while ProLynx's technology extends the half-life of drugs. Daniel Santi...
BioCentury | Apr 23, 2012
Emerging Company Profile

ProLynx: Hitting the links

...reduce a drug's biological activity and preclude intracellular action, according to ProLynx co-founder and President Daniel Santi...
...Disease focus: Drug delivery, endocrine/metabolic, cancer Clinical status: Preclinical Founded: 2009 by Gary Ashley and Daniel Santi...
BioCentury | Jun 30, 2008
Strategy

Pfizer fleshing out its model

...“What is novel about this deal is the unspecified nature of the research projects,” said Daniel Santi...
BioCentury | Jun 2, 2008
Strategy

Kosan Chronicles

...data miss the primary endpoint of change in levels of prostate-specific antigen (PSA).I. 2/14/06 - Daniel Santi...
BioCentury | Feb 20, 2006
Company News

Kosan management update

...Kosan Biosciences Inc. (KOSN), Hayward, Calif. Business: Cancer, Infectious Resigned: Daniel Santi as chairman and CEO; Robert...
BioCentury | Feb 16, 2006
Company News

Santi leaving Kosan

...Cancer and infectious disease company Kosan (KOSN) said co-founder Daniel Santi resigned as chairman and CEO. He...
BioCentury | Aug 22, 2005
Finance

Ebb & Flow

...proposed the financing on Aug. 5, the stock was at $9.65. KOSN Chairman and CEO Daniel Santi...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech Capital, increasing Alta's ownership in the polyketide developer to 9.9%. Company Chairman and CEO Daniel Santi...
BioCentury | Apr 30, 2001
Finance

Ebb & Flow

...Biotech Capital, increasing Alta's ownership in the polyketide developer to 9.9%. Company Chairman and CEO Daniel Santi...
BioCentury | Dec 18, 2000
Emerging Company Profile

Prospect Genomics Inc.

...Andrej Sali, Ken Dill, Peter Kollman, Irwin Kuntz, Richard Goold, Tod Klingler, William Rutter, and Daniel Santi...
Items per page:
1 - 10 of 13